Physician profile
Muhammad A Siddiqi
NPI 1811978000
$906.63
in general payments reported to CMS, 2019-2025
13 companies · $179 in 2025
The $179 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $395 · 2021: $41.84 · 2022: $12.78 · 2023: $194 · 2024: $83.91 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $439 · Education: $17.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $439.31 |
| Education | $17.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $183.27 | 2024-2025 | Azure Xt Dr Mri Surescan |
| Amgen INC. | $167.53 | 2019-2025 | |
| Abbott Laboratories | $160.88 | 2023 | Ensite Precision |
| Janssen Pharmaceuticals, INC | $83.89 | 2019 | |
| Novartis Pharmaceuticals Corporation | $44.90 | 2022-2025 | |
| Pfizer INC. | $42.35 | 2019 | |
| Bard Peripheral Vascular, INC. | $41.84 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.78 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $33.06 | 2023 | Arcalyst |
| Astrazeneca Pharmaceuticals LP | $32.67 | 2019 | |
| Abiomed | $29.98 | 2025 | |
| Biotronik INC. | $27.30 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $22.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Muhammad Siddiqi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.